Trelegy Dosing for COPD and Asthma
For COPD, the recommended dose of Trelegy (fluticasone furoate, umeclidinium, vilanterol) is one inhalation (100/62.5/25 mcg) once daily, while for asthma, the recommended dose is one inhalation (100/62.5/25 mcg or 200/62.5/25 mcg) once daily depending on severity. 1
COPD Dosing Recommendations
- Trelegy Ellipta is indicated as maintenance treatment for adults with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA 2
- The standard dose for COPD is fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg administered as one inhalation once daily 3
- Triple therapy should be reserved for selected, more severe COPD patients when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent 4
- Once-daily administration through the dry powder inhaler device has shown good adherence and patient preference 3
Asthma Dosing Recommendations
- For persistent asthma, long-acting β2-agonists like vilanterol should always be used in combination with inhaled corticosteroids, never as monotherapy 1
- Trelegy is available in two strengths for asthma management: 100/62.5/25 mcg and 200/62.5/25 mcg (fluticasone furoate/umeclidinium/vilanterol) 1
- The appropriate strength should be selected based on asthma severity and previous treatment response 1
Clinical Considerations for Dosing
- Regular monitoring of symptom control and lung function is essential to evaluate treatment response 1
- Patient preference, cost, and adverse effect profile should guide the choice of therapy 1
- The safety profile of Trelegy is generally good, without excess cardiovascular effects or pneumonia, though caution is needed in patients with comorbidities 5
- Once-daily dosing may improve compliance to long-term inhaled therapy compared to multiple daily dosing regimens 6
Special Populations
- For elderly patients with asthma and COPD, standard dosing applies, but the first treatment should be supervised 7
- In patients with glaucoma who require ipratropium (similar to umeclidinium), the use of a mouthpiece rather than a mask should be considered to prevent worsening of glaucoma 7
- The combination has been tested in numerous clinical trials involving thousands of patients, confirming its efficacy and safety profile 6